MedTrace Logo

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

NCT00467818 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-01-26

Study results available
· View outcomes & findings →

Summary

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses:

* Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism.
* Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism.
* Omega 3 fatty acids will be superior to placebo in improving functional ability.

Conditions

Interventions

DRUG

Omega 3 fatty acids

The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.

OTHER

Placebo

Same dosage as that of omega 3 fatty acids

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • University of Medicine and Dentistry of New Jersey

    lead OTHER

Principal Investigators

  • Sherie L. Novotny, MD · Division of Child and Adolescent Psychiatry at the University of Medicine and Dentistry of New Jersey

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467818 on ClinicalTrials.gov